Novel antidepressant drugs, arterial hypertension and cardiovascular disease
Vasiliki K Katsi, Maria Marketou, Georgia Vamvakou
1Cardiology Department, Hippokration Hospital, Greece, Vas. Sofias Avenue 114, Post code: 11527, Athens, Greece. vkkatsi@yahoo.gr.
Abstract:
Depression is a common mental health issue worldwide leading to disability, functional decline and increased mortality. Novel antidepressants have been developed during the last decades in order to treat depression syndromes. Some evidence suggests that major depression has been associated with the development of congestive heart failure and with adverse outcomes in patients with coronary heart disease. The purpose of the present article is to review the impact of novel antidepressant patent drugs on cardiovascular disease and arterial hypertension.
More Related Videos
05:57Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
06:15Effect of Yi-Nao-Jie-Yu Prescription on Post-Stroke Depression in Rats using Middle Cerebral Artery Occlusion Combined with Behavioral Restraint
Published on: January 9, 2026
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Drug Therapy
Antianxiety Medications
